Catal­ent touts GLP-1 man­u­fac­tur­ing; Telix grows ra­dio­phar­ma ca­pac­i­ty; Arc­turus ex­pands in Japan: #JPM24

Catal­ent’s stock $CTLT rose to the high­est it’s been in three months on Tues­day af­ter CEO Alessan­dro Masel­li em­pha­sized the CD­MO’s big pic­ture plan to man­u­fac­ture GLP-1 drugs.

Catal­ent had a rocky 2023, and is turn­ing to GLP-1 and gene ther­a­pies as a means to boost its rev­enue for this year. “Catal­ent has a lead­ing po­si­tion as a provider of ca­pac­i­ty to man­u­fac­ture GLP-1s and this will be one of the most ex­cit­ing ar­eas over the next few years,” Masel­li said at the CD­MO’s pre­sen­ta­tion at the JP Mor­gan Health­care Con­fer­ence on Mon­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER